

Jakob SchÅŕllhammer Knudsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4202060/publications.pdf>

Version: 2024-02-01

24
papers

245
citations

840728

11
h-index

996954

15
g-index

24
all docs

24
docs citations

24
times ranked

347
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: A Danish 24-year population-based study. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100291.	5.6	12
2	Identifying Valid Algorithms for Number of Lines of Anti-Neoplastic Therapy in the Danish National Patient Registry Among Patients with Advanced Ovarian, Gastric, Renal Cell, Urothelial, and Non-Small Cell Lung Cancer Attending a Danish University Hospital. <i>Clinical Epidemiology</i> , 2022, Volume 14, 159-171.	3.0	2
3	Development and validation of a model for predicting mortality in patients with hip fracture. <i>Age and Ageing</i> , 2022, 51, .	1.6	20
4	Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 520-529.	4.4	19
5	Systemic lupus erythematosus during pregnancy is not associated with school performance in offspring – A Danish population-based study. <i>Lupus</i> , 2021, 30, 228-237.	1.6	3
6	Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997–2017: Time trends in incidence and HbA _{1c} and glucose-lowering drug use before and after hypoglycaemia. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00227.	2.4	1
7	Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study. <i>Journal of the American Heart Association</i> , 2021, 10, e019356.	3.7	20
8	A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2354-2363.	4.4	2
9	Nationwide Trends in Cardiac Risk and Mortality in Patients With Incident Type 2 Diabetes: A Danish Cohort Study. <i>Diabetes Care</i> , 2021, 44, 2353-2360.	8.6	14
10	Acute pancreatitis: 31-Year trends in incidence and mortality – A Danish population-based cohort study. <i>Pancreatology</i> , 2020, 20, 1332-1339.	1.1	19
11	Trends in HbA1c and LDL Cholesterol in Patients With Type 2 Diabetes Receiving First-Time Treatment in Northern Denmark, 2000–2017: Population-Based Sequential Cross-Sectional Analysis. <i>Diabetes Care</i> , 2020, 43, e17-e19.	8.6	8
12	Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study. <i>PLoS ONE</i> , 2020, 15, e0229621.	2.5	27
13	Differences Between Randomized Clinical Trial Participants and Real-World Empagliflozin Users and the Changes in Their Glycated Hemoglobin Levels. <i>JAMA Network Open</i> , 2020, 3, e1920949.	5.9	13
14	Title is missing!. , 2020, 15, e0229621.		0
15	Title is missing!. , 2020, 15, e0229621.		0
16	Title is missing!. , 2020, 15, e0229621.		0
17	Title is missing!. , 2020, 15, e0229621.		0
18	Title is missing!. , 2020, 15, e0229621.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0229621.		0
20	Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries. British Journal of Pharmacology, 2019, 176, 386-399.	5.4	16
21	Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study. Journal of Diabetes, 2019, 11, 690-694.	1.8	3
22	Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails. Sexual Medicine Reviews, 2019, 7, 430-441.	2.9	19
23	Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. Diabetes Care, 2018, 41, e133-e135.	8.6	16
24	Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats. British Journal of Pharmacology, 2017, 174, 2563-2575.	5.4	31